Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHROME: Cardiovascular Disease Risk After Hepatitis C Eradication
NCT03823911Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of grazoprevir in hepatitis C (HCV), sponsored by University of Maryland, Baltimore. Started Nov 2018; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03823911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823911.